Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIMNASDAQ:OMGANASDAQ:SLXNNASDAQ:UPTD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$0.09-22.3%$0.10$0.06▼$0.47$6.61M0.76570,559 shs2.31 million shsOMGAOmega Therapeutics$0.13-21.8%$0.12$0.10▼$2.63$6.92M1.653.15 million shs4.81 million shsSLXNSilexion Therapeutics$0.96-4.6%$0.94$0.58▼$41.85$8.38M0.065.16 million shs328,631 shsUPTDTradeUP Acquisition$0.99-4.8%$1.51$6.88▼$33.00$2.15M0.12270,115 shs4,119 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech0.00%0.00%0.00%-32.70%-76.26%OMGAOmega Therapeutics0.00%0.00%0.00%0.00%-94.13%SLXNSilexion Therapeutics-2.88%+11.70%+8.10%-12.17%+100,999,900.00%UPTDTradeUP Acquisition0.00%+6.07%+4.00%-10.34%+4.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMAIM ImmunoTech1.6066 of 5 stars3.50.00.00.00.61.70.6OMGAOmega Therapeutics2.3233 of 5 stars3.40.00.00.02.01.71.3SLXNSilexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AUPTDTradeUP AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$2.752,908.75% UpsideOMGAOmega Therapeutics 2.80Moderate Buy$9.207,260.00% UpsideSLXNSilexion Therapeutics 3.00Buy$5.00418.67% UpsideUPTDTradeUP Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest UPTD, OMGA, AIM, and SLXN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2025SLXNSilexion TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $5.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$170K38.87N/AN/A$0.20 per share0.46OMGAOmega Therapeutics$8.10M0.85N/AN/A$1.05 per share0.12SLXNSilexion TherapeuticsN/AN/A$0.66 per share1.46($6.63) per shareN/AUPTDTradeUP AcquisitionN/AN/AN/AN/A($1.59) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$0.31N/AN/AN/A-12,594.21%-421.73%-147.54%N/AOMGAOmega Therapeutics-$97.43M-$1.33N/AN/AN/A-902.93%-213.13%-41.24%6/20/2025 (Estimated)SLXNSilexion Therapeutics$260KN/A0.00∞N/AN/AN/A-249.43%6/17/2025 (Estimated)UPTDTradeUP Acquisition-$1MN/A0.00∞N/AN/AN/A-3.38%N/ALatest UPTD, OMGA, AIM, and SLXN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025N/ASLXNSilexion TherapeuticsN/A-$0.26N/A-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/AOMGAOmega TherapeuticsN/AN/AN/AN/AN/ASLXNSilexion TherapeuticsN/AN/AN/AN/AN/AUPTDTradeUP AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75OMGAOmega Therapeutics1.001.611.61SLXNSilexion TherapeuticsN/A0.850.85UPTDTradeUP AcquisitionN/A0.090.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%OMGAOmega Therapeutics97.47%SLXNSilexion Therapeutics10.95%UPTDTradeUP Acquisition34.95%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%OMGAOmega Therapeutics8.50%SLXNSilexion Therapeutics33.00%UPTDTradeUP Acquisition55.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech2072.29 million68.74 millionNot OptionableOMGAOmega Therapeutics12055.37 million50.66 millionOptionableSLXNSilexion TherapeuticsN/A8.69 million1.07 millionN/AUPTDTradeUP Acquisition2,0212.17 million973,000Not OptionableUPTD, OMGA, AIM, and SLXN HeadlinesRecent News About These CompaniesEstrella Immunopharma stock plunges in market debut after SPAC mergerOctober 2, 2023 | msn.comSPAC TradeUp, Estrella Biopharma complete merger; shares to debut Oct. 2September 29, 2023 | msn.comTradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business CombinationSeptember 29, 2023 | finance.yahoo.comTradeUP (UPTD) Stock is Up: What's Going On?September 21, 2023 | benzinga.comTradeUp (NASDAQ: UPTD) up 67% - Hey, maybe a deal really will be done hereSeptember 15, 2023 | dhakatribune.comWhy TradeUP Acquisition (UPTD) Stock Is Rocketing HigherSeptember 1, 2023 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumIBM's AI Offensive: Assessing IBM's Path to Renewed GrowthBy Jeffrey Neal Johnson | May 8, 2025View IBM's AI Offensive: Assessing IBM's Path to Renewed GrowthUPTD, OMGA, AIM, and SLXN Company DescriptionsAIM ImmunoTech NYSE:AIM$0.09 -0.03 (-22.34%) As of 04/4/2025 This is a fair market value price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Omega Therapeutics NASDAQ:OMGA$0.12 -0.03 (-21.83%) Closing price 02/24/2025Extended Trading$0.12 0.00 (0.00%) As of 02/24/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Silexion Therapeutics NASDAQ:SLXN$0.96 -0.05 (-4.55%) Closing price 04:00 PM EasternExtended Trading$0.96 0.00 (-0.21%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.TradeUP Acquisition NASDAQ:UPTDTradeUP Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
